Abstract
Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.
Nabih I Abdou, Virginia Rider, Cindy Greenwell, Xiaolan Li and Bruce F Kimler
The Journal of Rheumatology May 2008, 35 (5) 797;
Nabih I Abdou
Virginia Rider
Cindy Greenwell
Xiaolan Li
In this issue
The Journal of Rheumatology
Vol. 35, Issue 5
1 May 2008
Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.
Nabih I Abdou, Virginia Rider, Cindy Greenwell, Xiaolan Li, Bruce F Kimler
The Journal of Rheumatology May 2008, 35 (5) 797;
Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.
Nabih I Abdou, Virginia Rider, Cindy Greenwell, Xiaolan Li, Bruce F Kimler
The Journal of Rheumatology May 2008, 35 (5) 797;